Bertè et al. tested IBD patients on biological treatment in Cagliari and Milan (Italy) and in Erlangen (Germany) and found an overall prevalence rate of 2.3% for serum IgG and 3.4% for IgA [15]. This evidence concerns the gene CD79A and inflammatory bowel disease.